Abstract
Randomized evaluation of the safety and efficacy of enoxaparin vs. unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have